Rydex S&P SmallCap 600 Pure Growth A holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Rydex S&P SmallCap 600 Pure Growth Fund Class A RYSGX
- NAV / 1-Day Return 64.83 / −1.68 %
- Total Assets 5.8M
-
Adj. Expense Ratio
1.550%
- Expense Ratio 1.550%
- Distribution Fee Level High
- Share Class Type Front Load
- Category Small Growth
- Investment Style Small Growth
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 3,105%
USD | NAV as of Jun 06, 2026 | 1-Day Return as of Jun 06, 2026, 2:25 AM GMT+0
Morningstar’s Analysis RYSGX
Will RYSGX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the RYSGX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of RYSGX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 14.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
ACM Research Inc Class A | 2.11 | 112,288 | Technology |
PTC Therapeutics Inc | 1.59 | 84,518 | Healthcare |
Primoris Services Corp | 1.49 | 79,166 | Industrials |
TransMedics Group Inc | 1.46 | 77,706 | Healthcare |
Adamas Trust Inc | 1.44 | 77,008 | Real Estate |
Arrowhead Pharmaceuticals Inc | 1.44 | 76,748 | Healthcare |
ARMOUR Residential REIT Inc | 1.39 | 74,072 | Real Estate |
Progyny Inc | 1.34 | 71,371 | Healthcare |
ACADIA Pharmaceuticals Inc | 1.33 | 70,716 | Healthcare |
DXP Enterprises Inc | 1.31 | 69,967 | Industrials |
United States